Case:
The discrimination of malignant melanoma from benign nevi may be difficult in some cases. For this reason, immunohistological and molecular techniques are included in the differential diagnostic toolbox for these lesions. These methods are time consuming when applied subsequently and, in some cases, no definitive diagnosis can be made. We studied both lesions by imaging mass spectrometry (IMS) in a large cohort (n = 203) to determine a different proteomic profile between cutaneous melanomas and melanocytic nevi. Statistical analysis of the IMS data revealed mass-to-charge ratio (m/z) peaks which varied significantly between the two tissue types. Our findings clearly show that discrimination of melanocytic nevi from melanoma is possible by IMS. (Casadonte et al., 2021)
Reference
Casadonte, R., Kriegsmann, M., Kriegsmann, K., Hauk, I., Meliß, R. R., Müller, C. S., & Kriegsmann, J. (2021). Imaging mass spectrometry-based proteomic analysis to differentiate melanocytic nevi and malignant melanoma. Cancers, 13(13), 3197. https://doi.org/10.3390/cancers13133197
Q1: Which of the below samples utilizes the source case correctly without plagiarism?
- A. Imaging mass spectrometry can be potentially used to a differential diagnostic tool to distinguish between nevi and cutaneous melanoma (Casadonte et al., 2021)
- B. According to Casadonte et al., (2021), distinctive diagnosis of cutaneous melanoma from nevi can be an uncertain and lengthy process. However, use of imaging mass spectrometry has shown immense potential by determining differences in the protein profile and mass to charge ratio between the two.
- C. Both A and B
- D. Neither A nor B
Q2: Which one of the below options represents the correct MLA format reference of the above case?
- A. Casadonte, Rita et al. “Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma.” Cancers vol. 13, 13 3197. 26 Jun. 2021, doi:10.3390/cancers13133197
- B. Casadonte, R., Kriegsmann, M., Kriegsmann, K., Hauk, I., Meliß, R. R., Müller, C., & Kriegsmann, J. (2021). Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma. Cancers, 13(13), 3197. https://doi.org/10.3390/cancers13133197
- C. Casadonte R, Kriegsmann M, Kriegsmann K, et al. Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma. Cancers (Basel). 2021;13(13):3197. Published 2021 Jun 26. doi:10.3390/cancers13133197
